

Hemato Oncology Testing Market - 2022

<https://marketpublishers.com/r/H03828634F89EN.html>

Date: December 2025

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: H03828634F89EN

Abstracts

The Hemato Oncology Testing Market was valued at USD 280 million in 2022 and is anticipated to reach by , at a CAGR of 0.048 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Hemato Oncology Testing Market.

This report delivers a comprehensive overview of the Hemato Oncology Testing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hemato Oncology Testing Market. The Hemato Oncology Testing Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Hemato Oncology Testing Market Scope:

By Type of Product & Service

Instruments

Reagents & Consumables

Services

By Technology

PCR (Polymerase Chain Reaction)

IHC (immunohistochemical)

NGS (Next-Generation Sequencing)

Cytogenetics

Others

By Cancer Type

Leukemia

Lymphoma

Multiple myelomas

Others

By End-user

Clinical Laboratories

Hospitals

Academic & Research Institutes

Others

Key Players

F. Hoffman-La Roche Ltd.

Abbott Laboratories

Qiagen N.V.

Thermo Fisher Scientific, Inc.

Illumina, Inc.

Bio-Rad Laboratories, Inc.

ICON PLC

Archerdx, Inc.

Invivoscribe, Inc.

Adaptive Biotechnologies(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Hemato Oncology Testing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hemato Oncology Testing Market. The Hemato Oncology Testing Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type of Products & Services
- 3.2. Snippet by Technology
- 3.3. Snippet by Type of cancer
- 3.4. Snippet by End-user
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Technological Advancements in Drug Diagnosis And Services
 - 4.1.1.2. Increasing Prevalence of Hematologic Cancer Globally
 - 4.1.2. Restraints
 - 4.1.2.1. Unfavorable And Uncertain Reimbursement Scenario
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Before COVID-19 Scenario

- 6.1.2. Present COVID-19 Scenario
- 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. BY TYPE OF PRODUCT & SERVICE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
 - 7.1.2. Market Attractiveness Index, By Type of Product & Service
- 7.2. Instruments
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Reagents & Consumables
- 7.4. Services

8. BY TECHNOLOGY

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
 - 8.1.2. Market Attractiveness Index, By Technology
- 8.2. PCR (Polymerase Chain Reaction) *
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. IHC (immunohistochemical)
- 8.4. NGS (Next-Generation Sequencing)
- 8.5. Cytogenetics
- 8.6. Others

9. BY CANCER TYPE

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 9.1.2. Market Attractiveness Index, By Cancer Type
- 9.2. Leukemia*

- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.2.3. Acute Myeloid Leukemia
- 9.2.4. Acute Lymphocytic Leukemia
- 9.2.5. Others
- 9.3. Lymphoma
- 9.4. Multiple myelomas
- 9.5. Others

10. BY END-USER

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 10.1.2. Market Attractiveness Index, By End-user
- 10.2. Clinical Laboratories*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Hospitals
- 10.4. Academic & Research Institutes
- 10.5. Others

11. BY REGION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
 - 11.2.1. Introduction
 - 11.2.2. Key Region-Specific Dynamics
 - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
 - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
 - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.2.7.1. The U.S.
 - 11.2.7.2. Canada
 - 11.2.7.3. Mexico
- 11.3. Europe

- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.3.6.1. Germany
 - 11.3.6.2. UK
 - 11.3.6.3. France
 - 11.3.6.4. Italy
 - 11.3.6.5. Russia
 - 11.3.6.6. Rest of Europe
- 11.4. South America
 - 11.4.1. Introduction
 - 11.4.2. Key Region-Specific Dynamics
 - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
 - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.4.6.1. Brazil
 - 11.4.6.2. Argentina
 - 11.4.6.3. Rest of South America
- 11.5. Asia-Pacific
 - 11.5.1. Introduction
 - 11.5.2. Key Region-Specific Dynamics
 - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
 - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.5.6.1. China
 - 11.5.6.2. India
 - 11.5.6.3. Japan
 - 11.5.6.4. Australia
 - 11.5.6.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
 - 11.6.1. Introduction
 - 11.6.2. Key Region-Specific Dynamics
 - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
 - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

- 13.1. F. Hoffman-La Roche Ltd.*
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Financial Overview
 - 13.1.4. Key Developments
- 13.2. Abbott Laboratories
- 13.3. Qiagen N.V.
- 13.4. Thermo Fisher Scientific, Inc.
- 13.5. Illumina, Inc.
- 13.6. Bio-Rad Laboratories, Inc.
- 13.7. ICON PLC
- 13.8. Archerdx, Inc.
- 13.9. Invivoscribe, Inc.
- 13.10. Adaptive Biotechnologies(*LIST NOT EXHAUSTIVE)

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Hemato Oncology Testing Market - 2022

Product link: <https://marketpublishers.com/r/H03828634F89EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H03828634F89EN.html>